Biodesix Receives CE Mark for Veristrat | GenomeWeb

Biodesix this week received an EU CE Mark for its Veristrat specimen collection and shipping kit, allowing the company to make Veristrat results available to physicians in the EU and other countries recognizing the CE Mark.

Veristrat is a blood-based proteomic diagnostic that identifies non-small cell lung cancer patients likely to respond to chemotherapy or the EGFR inhibitor Tarceva (erlotinib). Biodesix launched sales of the test in the US out of its CLIA lab in 2009 and has since performed more than 5,000 tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.